Related Experiment Video
Updated: Jun 24, 2026

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
Published on: August 1, 2013
A New Vaccine Candidate Expressing JUNV GP1-GP2 Against Argentine Hemorrhagic Fever Based on Baculovirus Surface
Carla Tomatis1,2, Mara C A M Aguiar2, Nancy Charo2
1Laboratorio de Patogénesis Viral, Instituto de Biotecnología y Biología Molecular (IBBM), CONICET-UNLP, Calle 49 y 115, 1900, La Plata, Buenos Aires, Argentina.
Abstract:
With the aim of developing a new vaccine candidate using a recombinant baculovirus (rBV) expressing the Junín virus (JUNV) GP1 and GP2 proteins on its surface, a pBacPAK9 vector containing the BV-GP64 signal peptide, the JUNV GP1-GP2 and the transmembrane domain of the vesicular stomatitis virus G (VSV-G) protein were synthesized. This plasmid was co-transfected with the bApGOZA bacmid into Sf9 cells. The rBV was recovered from the supernatant. Protein expression was confirmed with a human serum by Western blot and with an anti-GPC monoclonal antibody by IFI staining and virometry. In an ELISA test, mice immunized with rBV exhibited specific antibody levels that also showed neutralizing properties in a plaque reduction test compared to controls. Guinea pigs immunized with rBV and challenged with JUNV showed partial protection compared to the Candid#1 vaccine. We have developed an rBV surface display platform to validate a potential JUNV vaccine candidate.
Related Concept Videos
Arboviral Encephalitis
American Trypanosomiasis
Inhibitors Of Virion Release

